Demonstrating the Beneficial Effect of Low Protein Diet in

2 **Primary Sclerosing Cholangitis through a Randomized**

3 Clinical Trial and Multi-omics Data Analysis

- 4 Xiaole Yin^{1,*}, Gila Sasson^{2,*}, Zheng Sun¹, Shanlin Ke¹, Demsina Babazadeh³, Shaikh Danish
 5 Mahmood², Macie Andrews², Shelley Hurwitz², Tinashe Chikowore¹, Maia Paul², Nadine Javier²,
 6 Malav Dave², Alexandra Austin², Linda Gray⁴, Francene Steinberg⁵, Elaine Souza⁴, Christopher
- 7 Bowlus⁴, Yang-Yu Liu^{1,6, #}, Joshua Korzenik^{2, #}
- ¹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's
 ⁹Hospital, Harvard Medical School, Boston, MA 02115, USA
- ²Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital,
 Harvard Medical School, Boston, MA 02115, USA
- ³Center for Clinical Investigation, Brigham and Women's Hospital, Harvard Medical School,
 Boston, MA 02115, USA
- ⁴Division of Gastroenterology and Hepatology, University of California Davis School of Medicine,
 Sacramento, CA 95817, USA
- 16 ⁵Department of Nutrition, University of California Davis, College of Agricultural and 17 Environmental Sciences, Davis CA 95616, USA
- ⁶Center for Artificial Intelligence and Modeling, The Carl R. Woese Institute for Genomic Biology,
 University of Illinois at Urbana-Champaign, Champaign, IL 61801, USA
- 20 ** These authors contributed equally to this work.*
- [#] Correspondence should be addressed to J.K. (JKORZENIK@bwh.harvard.edu) and Y.-Y.L.
- 22 (yyl@channing.harvard.edu)

24 ABSTRACT

- 25 Primary sclerosing cholangitis (PSC), a progressive cholestatic hepatobiliary disease characterized
- by inflammation and fibrosis of the bile ducts, has a pathophysiology that is not understood. No
- 27 effective therapies exist. The only treatment option for PSC is liver transplant. We undertook a
- 28 pilot randomized trial of diet to investigate the pathophysiology of the disease, the role of diet and
- to advance potential therapy. We enrolled 20 patients with PSC and randomly assigned them to a
- 30 Low Protein/low sulfur Diet (LPD, n=10) or the Specific Carbohydrate Diet (SCD, n=10) for 8
- weeks. Results showed that low protein intake benefits PSC patients, whereas higher protein levels
 exacerbate the condition. We further identified gut bacterial markers useful for distinguishing LPD
- responders (mostly PSC with concomitant ulcerative colitis) from non-responders. Additionally,
- by integrating multi-omics data, we propose that this diet modifies the intestinal sulfur cycle
- reducing hydrogen sulfide (H_2S) production. Our findings provide an understanding of the
- 36 beneficial effect of LPD as well as insights into a possible key driver of inflammation in PSC.
- 37

38 **KEYWORDS**

- 39 Primary Sclerosing Cholangitis; Inflammatory Bowel Disease; Metabolomics; Low protein diet;
- 40 Specific carbohydrate diet; Sulfur metabolic pathway

42 INTRODUCTION

43 Primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease characterized by 44 inflammation and fibrosis of the biliary tree, can lead to debilitating consequences including end-

45 stage liver disease and malignancies. Currently, no therapy has been found to be effective for PSC,

46 other than liver transplant, which remains the mainstay of therapy. However, the disease can recur

47 after transplant. PSC is intimately associated with inflammatory bowel disease (IBD), particularly

- 48 ulcerative colitis (UC). Approximately 70-80% of patients with PSC also have underlying IBD [1,
- 49 2], but only around 3- 5% of UC patients will develop PSC [3]. Thus, the combination of the two
- creates a distinct disease phenotype, which is a prototypical disease of the gut-liver axis [1, 4].

51

52 The pathophysiology of PSC remains poorly understood. The paradigm of IBD is relied on as a 53 model to understand PSC, presuming an interaction between the environment, the microbiome and

54 immune system with a genetic predisposition [5, 6]. Other hypotheses suggest a toxic bile acid or

a cross reacting T cell response between the colonocytes and cholangiocytes [5, 7]. The immune

56 modifying approaches that can be effective in IBD do not benefit PSC. A distinct dysbiotic fecal

57 microbiome has been detailed in PSC, which overlaps with that of IBD [1, 4, 8]. While numerous

studies have investigated changes in the gut microbiome in the context of IBD [9-12], fewer have

59 focused on PSC [13-18].

60

Our approach to PSC in this study is based on the hypothesis that sulfur-containing amino acids 61 62 such as methionine may be substrates for sulfate-reducing bacteria to generate hydrogen sulfide (H₂S). H₂S production is likely coupled with increased bacterial degradation of mucin, which is 63 rich in cysteine and methionine [19, 20]. Further, H₂S can also impair colonocyte uptake and beta-64 oxidation of butyrate [21]. At higher levels, H₂S can be toxic to mitochondria, generating radical 65 oxygen species and activating the NLRP10 inflammasome, generating a broader inflammatory 66 67 reaction [22]. In this way, reducing H₂S by manipulating dietary sulfur content may limit cellular impairment and inflammation. Practically speaking, this would involve the reduction of sulfur-68 containing amino acids, which are primarily derived from animal and plant-based proteins. 69

70

71 In contrast, the comparator diet examined in this study, the Specific Carbohydrate Diet (SCD), is a popular diet among IBD patients that is grain-free and low in sugar and lactose, but does not 72 limit protein content. This diet has been studied to a limited degree in IBD with variable 73 74 effectiveness [23, 24]. The SCD excludes the intake of complex carbohydrates, disaccharidecontaining foods, grain, corn, potato, and dairy while permitting carbohydrates obtained from 75 76 fruits, honey, some vegetables, and fermented vogurt. The SCD is based on the principle that 77 specifically selected carbohydrates in SCD require minimal digestion, so they are subsequently 78 well absorbed, avoiding further gut microbial metabolism.

79 Diet composition may influence gut microbial activity in PSC, both through supporting or

80 enhancing the growth of particular bacterial communities and modifying metabolic profiles. These

adaptations may consequently influence disease progression through the gut-liver axis [25-29]. Yet,

the interplay between these parameters is complex and poorly understood [4] especially with

regard to its effect on disease course [30, 31]. Despite the strong patient interest, clinical trials

targeting dietary interventions specifically for PSC are notably lacking. To date, only one study has examined a gluten-free diet in individuals with PSC and associated colitis, and it failed to

86 demonstrate clinical or biomedical improvement [32].

87

88 In this study, we conducted a pilot randomized controlled trial to assess the clinical efficacy of a

89 low-protein diet (LPD) compared to the SCD in PSC (Fig. 1a & 1b), and leveraged high-

90 throughput technologies (shotgun metagenomic sequencing and global untargeted metabolomic

91 profiling) and multi-omics data analyses to gain mechanistic insights into response to dietary

92 intervention (**Fig. 1c**).

93

94 **RESULTS**

95 **Patient characteristics**

96 We screened ~100 individuals with PSC, and 25 met eligibility criteria and 5 eligible individuals

97 chose not to participate prior to randomization. Ten participants were randomly assigned to the

LPD and ten to the SCD (Fig. 1a, Fig. 1b & Table 1). Participant characteristics were balanced

99 between the groups. Two participants withdrew due to cholangitis, and their data until withdrawal

- 100 were incorporated into the analysis.
- 101 Participants in the LPD group demonstrated lower protein consumption in 3-day food recordings
- at all study time points during dietary intervention (week 2 to week 10) compared to SCD group

participants (Wilcoxon rank-sum test, 4.57e-05 < p-value < 0.010), supporting the compliance with

- 104 the dietary interventions (**Fig. 2a**).
- 105

106 LPD benefits PSC patients, but SCD does not

107 Comparing the ALP levels at W4 and W8 with those at W0, we found that LPD led to improvement

108 (i.e., decrease in ALP) in eight of the ten individuals (80%), with six of them (75%) returning to

their baseline ALP level when dietary interventions were removed at W10 (Fig. 2b). In contrast,

110 only two of the ten participants (20%) in the SCD group responded to SCD (i.e., with lower ALP

- 111 levels than their baseline levels). Moreover, for most of the participants in the SCD group, their
- ALP values did not appear to be affected after discontinuing the dietary intervention, suggesting
- that SCD may not be a potentially effective treatment for PSC. For those eight participants who

responded to LPD, hereafter referred to as LPD-responders, their ALP values were reduced by 115 $18.5\% \pm 10.4\%$ at W4 (i.e., after two weeks of treatment), and by 22.6% $\pm 15.6\%$ at W8 (i.e., after

116 another four weeks of treatment).

117 When accounting for an ALP decrease of at least 10%, LPD showed efficacy in 60% of patients,

118 compared to a 20% efficacy rate in SCD. With a reduction of at least 20%, LPD demonstrated

efficacy in 30% of patients, while SCD showed a 10% rate. Considering a decrease of at least 30%,

- 120 LPD maintained its efficacy in 30% of patients, with no cases of efficacy in SCD. Finally, with an
- ALP decrease of at least 50%, LPD is effective in 10% of patients, with SCD also showing no
- cases of effectiveness. Changes of other parameters, including Aspartate Aminotransferase (AST)
- and Alanine Aminotransferase (ALT) values, during the intervention were shown in **Fig. S1**.

Direct evidence obtained from Lasso Regression analysis revealed a significant positive correlation between the dietary methionine levels and the ALP levels (**Fig. 2c**). This finding indicates that lower methionine intake is associated with lower ALP levels compared to baseline values. However, it is crucial to note that this relationship is correlative rather than causative

values. However, it is crucial to note that this relationship is correlative rather than causative.

In addition to methionine, levels of magnesium, total sugar, iron, total folate, other amino acids, vitamin K and vitamin D were also positively associated with the ALP levels (Fig. 2c). By contrast, the levels of histidine, calcium, tryptophan, soluble dietary fiber, beta-carotene, starch, and vitamin

- 131 B-12 were negatively associated with the ALP levels. At the same time, we observed that
- 132 carbohydrate consumptions (nutrient density) exhibited significant differences between LPD and
- 133 SCD, with LPD being higher than SCD at all time points during dietary intervention (week 2 to
- 134 week 10) compared to baseline (Wilcoxon rank-sum test, 0.0014 < p-value < 2.17e-05) (Fig. S2).
- 135

136 Three disease categories respond differently to dietary intervention

We performed a stratified analysis to determine if comorbid IBD influences ALP response to 137 dietary interventions. Though the numbers of individuals in each subgroup were small, marked 138 differences were evident for certain disease categories. For instance, for PSC-UC patients (n= 10 139 in total), LPD (n=6) was significantly more effective in lowering ALP than SCD (n=4), (Wilcoxon 140 141 rank-sum test, p-value = 0.038). Moreover, all the PSC-UC patients in the LPD arm responded to LPD assessed by decreasing ALP levels, see Fig. 2d. For PSC-CD patients (n= 3 in total), there 142 was only one patient in the LPD arm (n=1), and this patient responded to LPD. Interestingly, for 143 PSC patients without IBD (PSC-alone) (n=7 in total), one patient in the LPD arm (n=3) responded, 144 while no response in SCD (n=4). Moreover, the two interventions didn't demonstrate any 145 significant difference in reducing ALP levels (Fig. 2f). 146

- 147
- 148
- 149

150 Gut microbial features distinguish LPD responders from non-responders

151 Given the efficacy of LPD, we aimed to determine distinguishing microbial biomarkers between

LPD responders and non-responders using shotgun metagenomic sequencing data. We found that 152 the alpha diversity (measured by the Shannon index) of stool samples in the PSC-UC group was 153 significantly lower than that in the PSC-CD and PSC-alone groups (Fig. S3a & Fig. S3b, 154 Wilcoxon rank-sum test, p-value = 0.016 and p-value = 0.00062, respectively). Samples in each 155 category were clustered together and distinct from the other two groups (PERMANOVA p-156 value=0.001, F=3.53) (Fig. S2c). When individuals were simply classified into responders 157 158 (individuals showing reduced ALP) and non-responders (individuals showing reduced ALP), variations in alpha diversities and differences in beta diversity can be found in Fig 3a, Fig. S4 & 159 Fig. S5. The clusters of LPD were separated from LPD non-responders in the PCoA plot based on 160

161 the Bray-Curtis dissimilarity, suggesting that gut microbiota is key in differentiating response

162 outcomes (Fig. 3a). Similar results were revealed by UMAP clustering (Fig. S4b).

To account for three disease categories as covariates and to eliminate random effects of inter-163 individual variation due to temporal changes, we employed MaAsLin2 to perform a multivariate 164 linear regression analysis on the taxonomic profiles of the stool samples (see Methods, Formula 165 1). We aimed to find microbial features that significantly differentiate LPD responders from LPD 166 non-responders (with cutoff p-value < 0.05 and q-value < 0.2). We identified 21 (or 15) microbial 167 species as significantly positively (or negatively) associated with responders, respectively (Fig. 168 **3b**). Among these, Ruminococcus gnavus, Blautia caecimuris, Blautia producta, Enterocloster 169 bolteae, and Flavonifractor plautii, were more abundant in responders across samples of all three 170 171 disease categories. Conversely, Clostridium bacteria, Roseburia bacteria, Senegalimassilia 172 anaerobia, and others were found in much lower abundance in responders.

In the heatmap of microbial profiles, samples are clustered based on the similarity of their bacterial 173 174 structures (Fig. 3b). Interestingly, we found that the selected bacterial markers not only differentiate responders from non-responders but also distinguish between disease categories. For 175 instance, PSC-UC samples are clustered together, as are PSC-CD samples, while non-responders, 176 who were all PSC-alone, also form a distinct group. Samples from the same individuals are 177 178 clustered together on both the heatmap (Fig. 3b) and the PCoA plot (Fig. 3a), indicating a personalized gut microbiome, i.e., intra-individual differences are smaller than inter-individual 179 ones. Therefore, disease categories can also be considered as a general predictor of LPD response. 180

181

182 Gut metabolome is affected by multiple variables

To better understand metabolomic parameters of LPD response, we conducted the global untargeted metabolomic analysis of all stool samples using the ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) (see **Methods**). A total of 1,428 metabolites were quantified from at least one sample in this study, and a subset of 1,057

metabolites with known chemical names and corresponding identities in at least one of the 187 following three databases: the Human Metabolome Database (HMDB) [33], the Kyoto 188 Encyclopedia of Genes and Genomes (KEGG) database [34], and the PubChem database [35]. 189 Metabolite compositions exhibited greater temporal variations within individuals than microbial 190 191 profiles, as indicated by ordination analysis (Fig. 3a versus Fig. 3c, Fig. S4a versus Fig. S4c), revealing that after dietary interventions, samples from the same individuals at different time points 192 were interspersed with samples from others, leading to a mixed clustering pattern. Using the 193 previously described multivariate linear regression model, we identified 29 metabolomic markers 194 associated with clinical outcomes (p-value < 0.05 and q-value < 0.2) (see Methods, Formula 1). 195 Of these, 27 metabolites were positively associated with LPD responders, while 2 metabolites were 196 negatively associated (Fig. 3d). The intensity of metabolite markers in LPD responders versus 197 LPD non-responders was less distinctive than that observed with microbial markers (Fig. 3d). 198 Additionally, in contrast to microbial markers, clustering based on metabolite markers composition 199 200 did not show a clear correlation with disease category (Fig. S6). Moreover, the observable intraindividual variation in these markers after dietary intervention indicates baseline metabolic profile 201 cannot serve as a reliable predictor of response outcome to diet intervention, unlike microbial 202 markers. 203

204

205 Sulfur-related metabolites predict the LPD-induced changes

206 Diet-induced temporal changes in metabolite profiles were further analyzed to determine the primary mechanism underlying the effect of LPD. We employed multivariate linear regression 207 models, which are different from those described earlier, to distinguish metabolite markers under 208 LPD intervention (W4 and W8) from baseline (W0), incorporating the individual as a random 209 effect and disease category, age, gender, and BMI as fixed effects (see Methods, Formula 2). We 210 211 identified 39 metabolite markers that significantly changed throughout LPD compared to baseline (p-value < 0.05 and q-value < 0.25), 21 of which have known chemical annotations. Of these, 6 212 (or 15) metabolites' abundances increased (or decreased) with LPD. Notably, the majority of 213 depleted metabolites (8/15) were either amino acids or fatty acids. Among the 6 enriched 214 215 metabolites, four were classified as carbohydrates (n=1), medium-chain hydroxy acids (n=1), tricarboxylic acids (n=1), or quinoline carboxylic acids (n=1) (Fig. 4a). 216

To identify metabolic pathways that are significantly altered, we performed metabolite set enrichment analysis (MSEA) [36, 37] using all the 21 metabolite features that significantly changed throughout treatment and with known chemical names. We found significant changes in purine metabolism (MetaboAnalyst v5.0, p-value = 0.0083), sulfur metabolism (p-value = 0.0083), and biotin metabolism (p-value = 0.021) with LPD. Notably, sulfur metabolism had the highest enrichment ratio (enrich = 6.26), suggesting it may be a primary mechanism behind the effect of LPD (**Fig. 4b**).

To extract metabolites potentially converted from or to sulfur-containing chemicals, out of the 224 1,043 detected metabolites, we identified 40 sulfur-related metabolites referenced in the SMILES 225 database [38]. Four key metabolites were found to have significantly changed (Fig. 4c-f & Fig. 226 4k). Methionine (Wilcoxon signed-rank test, p-value=0.039 at W4) and its oxide methionine 227 228 sulfone (Wilcoxon signed-rank test, p-value=0.015 at W8) were significantly depleted compared to baseline. This suggests that reduced protein intake led to a continual decrease in methionine and 229 methionine sulfone in the gut. Taurine significantly enriched by W8 (Wilcoxon signed-rank test, 230 p-value=0.047) compared to baseline. Cysteine level varied over time, increasing at W4 but 231 decreasing at W8. Notably, cysteine intensity changes showed a significant negative association 232 with ALP changes, indicating that cysteine accumulation correlates with lower ALP values 233 (Spearman correlation: R = -0.42, p-value= 0.0172) (Fig. 4j). Furthermore, in association with 234 taurine accumulation, significant changes in luminal bile acids were observed. Notably, we found 235 the levels of cholic acid was significantly elevated with LPD, while taurocholic acid were 236 237 significantly decreased with LPD (Fig. 4k & Fig. S7, pathways referred to KEGG database [45]) A complete list of significantly changed sulfur-containing metabolites (n=45) and bile acids (n=19) 238

- is in Table S1.
- 240

241 Changes in functional metagenomic features associated with LPD intervention

To explain the microbial contributions to the metabolite variations and to understand the temporal 242 243 changes of functional consequences of the microbial community leading to response, we profiled 244 gene families in all stool samples. Based on the shotgun metagenomic sequencing data, we analyzed the functional gene profiles using HUMAnN3.6 and identified 2,427 enzymes (KOs) 245 from different bacterial species. Although the functional pathways were relatively stable across 246 individuals and across times (Fig. S8), due to microbial functional redundancy, we then selected 247 248 genes that significantly changed throughout dietary intervention in LPD responders by fitting a multivariate linear model to each enzyme, adjusting for the random effect of each individual and 249 other covariates (see Methods, Formula 2). In total, 99 (or 11)genes significantly increased (or 250 decreased) at W4 and W8 compared to baseline (W0) (target p-value < 0.05). 251

252 We focused on genes involved with sulfur metabolism to decipher the relationship between sulfur-253 related metabolite changes and microbial functional changes. We referred to a comprehensive list of 74 genes involved in microbial sulfur metabolism in humans [39, 40]. Of these, 27 were detected 254 in at least one sample in this study, with 6 (or 5) of these genes significantly decreasing (or 255 256 increasing) during intervention in LPD responders (Wilcoxon rank-sum test, p-value < 0.05), and 4 genes increasing with marginal significance (0.05 < p-value < 0.06) (Fig. 4k & Table S2). 257 Interestingly, LPD led to a reduced amount of cysJ, a critical enzyme for producing hydrogen 258 sulfide (H₂S) from sulfite, and a reduced amount of *dvcD*, key for H₂S production from cysteine 259 (Fig. 4k) [39, 40]. Conversely, the *cvsK* gene, involved in metabolizing H₂S in the biosynthesis of 260 cysteine, increased throughout LPD (Fig. 4k) [39, 40]. Similarly, there was an increase in the bsh 261

gene that metabolizes taurine and aids in the deconjugation of tauro-conjugated bile acids excreted to the gut from the biliary tree (Fig. 4k) [41]. These findings highlight the relationship between microbial functional profile with metabolite changes, supporting the potential mechanistic role of altered sulfur metabolism in attenuating luminal inflammation and enhancing ALP reduction in PSC.

267

268 Bacterial species associations with functional genes

269 Given the significant changes in microbial functional profiles, we explored the bacterial species connected to these enzymes. We constructed a large-scale association network among functional 270 genes, metabolites, and bacterial species. To identify covariations strictly linked to diet change, we 271 first residualized each feature in either measurement type using the same multivariate model 272 employed to determine differential changes in responders during LPD intervention (see Methods, 273 274 Formula 2). This residualization process, using longitudinal measurements, minimizes interindividual variation and highlights within-person associations over time, considering diagnostic 275 categories as covariates. The resulting network contained 74 edges linking genes and metabolites, 276 906 edges between genes and species, and 57 edges linking gene pairs, where at least one 277 connected gene was sulfur-related and the paired correlation was significant (Spearman correlation 278 FDR < 0.05) (Fig. 5a & Table S3). The network encompassed 331 nodes spanning features from 279 three measurement types. *tauD*, a gene converting taurine to sulfite (further convertible to H_2S) 280 (Fig. 4k), was central in the network with the most connections (n = 174) to different bacterial 281 species. However, for most of these species (90.2%), the abundance change of a single species was 282 not significant (multivariate model p-value < 0.05). Eggerthella lenta, significantly positively 283 associated with *tauD* (Spearman correlation FDR < 0.05) (Table S3), showed a marked decrease 284 in abundance during LPD intervention (Wilcoxon rank-sum test p-value = 8.7e-3; multivariate 285 model: p-value = 0.016) (Fig. 5d, Fig. S9 & Table S4). This species is critical in diet-induced 286 changes, because it is also linked to dmsC (K00185), involved in the conversion from methionine 287 to sulfite (Fig. 4k), estimating via the taxonomic stratified functional profile by HUMAnNv3.6, 288 and carries 10 other genes associated with sulfur metabolism, including iscS, and ahcY, which are 289 genes significantly reduced with LPD (Wilcoxon rank-sum test, p-value < 0.05) as well (Table 290 291 S2). Genes cysJ and dcyD carried the second and fourth most connections, contributed by 92 and 292 74 different species, respectively (Fig. 5a & Table S3). These two genes were significantly interrelated (Spearman correlation coefficient = 0.95, R = 5.06e-11) and associated with other 293 reduced genes including *tauD*, *dmsC*, *aspC*, and *iscC*. However, these genes were contributed by 294 295 more than a single bacterium because no significant changes were found in any single species in cysJ or dcyD based on stratified abundance. bsh, a gene that metabolizes taurine and aids in the 296 deconjugation of tauro-conjugated bile acids, did not exhibit positive correlations in any species 297 in the complex association network. However, the taxonomic stratified analysis showed a 298 significant increase in the abundance of bsh in Roseburia intestinalis in LPD responders (Wilcoxon 299 300 rank-sum test, p-value = 1.7e-3), a decrease in the SCD group and no change in LPD nonresponders (Fig. 5b & Table S5). Notably, *Roseburia intestinalis* is a key bacterium in sulfur metabolism, containing 10 relevant genes that significantly changed, including *cysK*, *metK*, *dcm*,

303 metB, metY, luxS, and others (Fig. 5c & Table S5). Not only gene abundances, the bacterial

abundance of *Roseburia intestinalis* showed a marked increase in LPD responders (Wilcoxon rank-

sum test: p-value = 3.8e-3; multivariate model: p-value = 4.4e-4) (Fig. 5d, Fig. S8 & Table S4).

306

307 **DISCUSSION**

The relationship between diet-microbiome-host interactions and their influence on the course of PSC is complex and poorly understood. To our knowledge, this is the first randomized controlled trial comparing the effects of two diets to assess a biochemical improvement in PSC through their modulatory effects on the gut microbiome. We observed that protein restriction was associated with improvement in ALP, while a diet limited in carbohydrates but not protein yielded no such benefit.

314 Moreover, the integration of multi-omics measurements, including state-of-the-art whole metagenomic sequencing and untargeted metabolite measurements, enabled us to reveal 315 significant diet-induced changes in sulfur metabolism, purine metabolism, and biotin metabolism. 316 317 Previous studies have suggested that H₂S can be generated from multiple sulfur-containing amino acids, or from sulfate-reducing bacteria [19, 42]. In turn, H₂S overproduction inhibits the 318 cytochrome c oxidase activity in the human mitochondrial respiratory chain, thus disrupting the 319 mitochondrial energy metabolism and promoting mucosal inflammation [43]. Although a 320 potentially detrimental role of H₂S has been linked to intestinal dysbiosis, much less is known 321 about its relationship to liver disease progression. Our study provides evidence of significant diet-322 induced changes in sulfur-containing metabolites and related enzymes. Notably, decreased protein 323 intake led to reduced levels of methionine and its oxide, associated with lower microbial enzymatic 324 activity, particularly in enzymes involved in H₂S production. We also observed a decrease in H₂S-325 326 producing bacteria, including Eggerthella lenta, significantly associated with enzymes like tauD, dmsC, iscS, and ahcY. Thus, our data confirm, from various perspectives, that a low-protein diet 327 regulates H₂S production by correcting the imbalance in sulfur metabolism. 328

329 Alterations in sulfur metabolism as the primary mechanism for the beneficial effects of low protein are also reflected in the accumulation of taurine and cysteine. This accumulation results from 330 increased activity of the bsh gene, associated with taurine accumulation, and the malY and metB 331 genes, linked to cysteine production, when the conversion of taurine and cysteine to H₂S was 332 significantly reduced, as discussed previously. An unhealthy gut microbiome that lacks the 333 required deconjugation of host primary bile acids into secondary bile acids, impairs liver and gut 334 function, in addition to overall health [44, 45]. Importantly, our data showed that taurine 335 accumulation and cholate increase correspond with the increase of deconjugation genes, such as 336 337 bsh, in response to taurocholate—a taurine-conjugated bile acid, indicating amelioration of the 338 imbalanced gut microbiome in PSC patients with restricted protein intake. Intriguingly, the bacteria found to increase after LPD, primarily carriers of *bsh, cysK, malY*, and *metB* genes, include *Roseburia intestinalis*. The increase in *Roseburia intestinalis*, known for its beneficial role in
producing beneficial short-chain fatty acids which possess anti-inflammatory properties [46, 47],
suggests a rebalancing of the bacterial structure in PSC patients, where deconjugation is otherwise
lacking compared with healthy individuals. Therefore, our data suggest that LPD might enhance

- the gut's deconjugation of primary bile acids, offering potential protective mechanisms against
- 345 inflammation and helping to restore a healthier microbial balance/composition.
- While the role of H₂S has not been previously investigated in PSC, more has been done to 346 347 investigate its role in UC with a small but largely supportive literature [48, 49]. An increase in sulfate-reducing bacteria has been associated with UC and flares in particular [50, 51]. With regard 348 to diet, flares have been found to be associated with a higher protein diet [52]. Higher protein diets 349 have been demonstrated to increase H₂S production by intestinal bacteria increasing sulfate-350 reducing bacteria [53]. Several interventional studies of a low sulfur diet have shown to be of 351 benefit in UC though more detailed investigations into the metagenomic and metabolomic 352 elements and pathologic pathways have not been part of those studies [54]. Still, the intimate 353 connection between UC and PSC would suggest these studies might be relevant and H₂S may offer 354 a potential physiologic link between these diseases. 355
- In addition to our findings regarding sulfur metabolism, we were able to identify microbial signatures that can be used to predict response to LPD. Besides, we observed that the majority of responders had concomitant UC, and that the predictive microbial signatures were enriched in all baseline samples of PSC-UC participants. Collectively, these findings serve to enhance patient selection for this intervention and warrant further exploration in larger cohorts.
- Although this study provides significant insights into better understanding PSC pathophysiology, there are several limitations, including a small cohort size and lack of a traditional control arm. Future inclusion of healthy controls or IBD-only controls could offer a more comprehensive understanding of mechanisms involved in disease progression. Additionally, while the 8-weeklong intervention and 4-week self-guided follow-up provided interesting findings, exploring the longer-term effects and potential changes after prolonged intervention remains a key area for future research.
- Overall, the well-documented dietary adherence and records of different subgroups of individuals with PSC, in combination with high-throughput technologies and the multi-omics approach, enabled us to determine the clinical, microbial and metabolic signatures associated with responsiveness to dietary interventions. This study enhanced our understanding of PSC pathogenesis and paved the way for large-scale dietary intervention studies in PSC.
- 373
- 374
- 375

376 **METHODS**

Study setting and design. This was a decentralized randomized controlled trial across the United
States. Participant enrollment occurred between August 28, 2020 and June 9, 2021. Recruitment
occurred in-person and by video remotely, and participants were able to conduct the study remotely.
Recruitment was facilitated via physician referral, patient advocacy organizations (PSC Partners
Seeking a Cure and Consortium for Autoimmune Liver Disease), and self-referral.

382 Eligible participants were randomized in 1:1 fashion to the LPD and SCD at a screening visit (week 0, W0, referred to as "baseline") during which medical records were reviewed, eligibility was 383 assessed and bloodwork, stool, baseline Food Frequency Questionnaire (FFQ) and Patient-384 reported Outcome Measures (PROMs) were collected. Thereafter, participants were given two 385 386 weeks for education on appropriate guidelines for the assigned dietary intervention as well as procurement of food. The dietary intervention began at week 2 (W2) and lasted for 8 consecutive 387 weeks until week 10 (W10) under dietitian supervision, with an option to continue self-directed 388 for an additional 4 weeks (W14). There was a total of 7 video visits with a research dietitian. 389 390 Additional dietary counselling was also offered between screening and baseline visits to provide further instruction and support. Three-day food diaries, bloodwork, stool samples and PROMs 391 were collected at 7 points throughout the study (Fig. 1a). 392

Eligibility criteria. Adults between 18 and 70 years of age with large-duct PSC diagnosed by 393 typical cholangiogram findings with no evidence of a secondary cause of sclerosing cholangitis 394 395 and with serum ALP >1.5 times the upper limit of normal (ULN) were potentially eligible for enrollment. Participants with concomitant UC or CD were eligible if the Simple Clinical Colitis 396 Activity Index or Harvey-Bradshaw Index, respectively, were <5. Additional inclusion criteria 397 included platelet count > 150,000/mm³, serum albumin > 3.3 g/dL, serum creatinine < ULN, and 398 stable dose or no use of ursodeoxycholic acid (UDCA) for at least 3 months prior to enrollment 399 for those taking and not taking UDCA respectively. Proficiency in English and ability to complete 400 PROMs independently was also a requirement. Exclusion criteria included pregnancy or lactation, 401 ALT above 10 times the ULN, total bilirubin at least twice the ULN, INR >1.2, decompensated 402 403 cirrhosis, small duct PSC, other etiologies of liver disease, positive AMA, history of liver transplantation, history of hepatocellular carcinoma or cholangiocarcinoma, ascending cholangitis 404 within 90 days of enrollment, antibiotic use within 6 weeks prior to enrollment or planned during 405 the study period, current vegetarian or adherence to the SCD, nut allergy given that nut flour is a 406 407 dietary staple of many SCD recipes and nut allergy could compromise diet adherence, celiac disease, history of malignancy within 5 years with the exception of adequately treated cervical 408 carcinoma in situ and basal or squamous cell carcinoma, inability to complete a dietary log, or 409 concurrent participation in another therapeutic clinical trial. Medical records of all individuals 410 were reviewed at the screening visit to determine eligibility. 411

412

413 Dietary interventions. The LPD was developed according to 2015-2020 USDA Dietary
 414 Guidelines of a vegan diet which state the diet should be rich in grains, legumes, nuts and other

plant-based proteins, with a focus on increased consumption of fruits, vegetables and healthy fats 415 [55]. In addition to these guidelines, the diet restricted high-sulfate items, defined as 416 containing >100mg sulfur per 100g of food item. A typical vegan diet contains approximately 417 2.3g/day of sulfur-containing amino acids, falling within the estimated range of appropriate sulfur 418 419 content of 2.1-3.0 g/day [56]. The SCD followed the dietary guidelines detailed in the book Breaking the Vicious Cycle by Elaine Gottschall [57]. The detailed LPD and SCD dietary guidance 420 is provided in Table S6. Participants were provided with education materials, recipes and a food 421 procurement stipend for their assigned diet at the screening visit. Total daily energy intake was 422 calculated by the Mifflin St. Jeor equation using an activity factor of 1.3 reflecting light activity 423 and exercise level. 424

425 Assessment of diet composition and adherence. Habitual diet was recorded using a validated FFQ at the screening visit (week 0) that queried dietary habits over the preceding year. During the 426 intervention phase, 3-day food diaries were recorded at five time points (weeks 2, 4, 6, 8, 10) (Fig. 427 1a). One of these days included a weekend. Participants recorded diet in real-time via 428 429 photodocumentation of each meal, snack and beverage using a smartphone application that was customized for this study. The application transmitted time-stamped photographs taken during the 430 recording period, along with a reference-sized study ruler to assess relative sizes of food items. 431 Caloric intake and micronutrient composition of each meal was calculated and analyzed using 432 Food Processor, a program with the ability to quantify protein intake, as well as cysteine, 433 434 methionine and taurine content as a proxy for sulfur.

In order to optimize compliance, the research team reviewed dietary records in real-time and discussed barriers to compliance with participants when appropriate. Dietary analysis was also performed at the conclusion of each diet recording period to further assess compliance. Feedback was provided to participants via the application if there were fewer than 2 entries per day or if a 24-hour period elapsed without any recording. The study coordinator followed up by email and/or telephone if no confirmation was received from the participant within 24 hours of the communication.

442 Outcome measures. The outcome measures were response in alkaline phosphatase (ALP),
443 Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST).

Whole Metagenomic Sequencing. Stool samples were collected at home frozen within 15
minutes of collection and maintained at -80 °C before sending to Diversigen for DNA extraction,
whole-genome shotgun library preparation, and Illumina sequencing. The metagenomics
sequencing targeted approximately 5 Gb of sequences per sample, utilizing 151 base pair pairedend reads.

Read-level quality control and metagenomic profiling. Raw sequencing reads underwent
 quality control (QC) using KneadData version 0.12.0
 (<u>https://huttenhower.sph.harvard.edu/kneaddata/</u>). Briefly, the first step of this process utilizes
 Trimmomatic version 0.39 for forward/reverse adapter removal, low-quality reads trimming and

tandem repeats removal using the default parameters. Contaminants from the host (human)
genomes were subsequently identified and removed by mapping against the reference database
(hg37 and human contamination) using Bowtie2 version 2.5.1.

456 After QC, each dataset contained over 2.8 Gb of clean, paired-end reads. Clean reads were then taxonomically profiled using MetaPhlAn4 version 4.0.6 [58], which includes an updated database 457 significantly larger than the previous version 3.1. Species-level relative abundances were 458 considered all this study. Species that failed to exceed 0.1% average relative abundance or were 459 detected in less than 4 samples were excluded. Functional profiling was performed using 460 HUMAnN3 version 3.6 under default parameters according to the UniRef90 definition to get the 461 relative abundance of gene families in the unit of reads per kilobase (RPK) [59]. And MetaCyc 462 provides pathway definitions to group gene families to get pathway abundance and coverage. The 463 abundances of gene families were further transformed into the unit of copies per million (CPM), 464 and we regrouped the gene families to KEGG Orthogroups (KOs), to filter out 74 gene families 465 that were involved in the microbial sulfur transformation. 466

Global untargeted metabolomics. Stool samples were sent to Metabolon for global untargeted 467 metabolomics following the standard procedure. Briefly, samples were pretreated to remove 468 proteins and recover chemically diverse metabolites. The resulting extract was divided into five 469 fractions: two for analysis by two separate reverse phases (RP)/UPLC-MS/MS methods with 470 positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with 471 negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, 472 and one sample was reserved for backup. All methods utilized a Waters ACQUITY ultra-473 performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high 474 resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) 475 source and Orbitrap mass analyzer operated at 35,000 mass resolution. Raw data were extracted, 476 peak-identified and QC processed using the contractor's hardware and software. Compounds were 477 identified by comparison to library entries of purified standards or recurrent unknown entities. The 478 intensity of each compound was quantified using area-under-the-curve. 479

Metabolite-level quality control and pretreatment. Metabolite intensities were normalized as z-480 scores: $\frac{x_i - \mu}{\sigma}$, where, x_i represents the original metabolite intensity, μ is the mean value of that 481 metabolite intensity across all samples, and σ is the standard deviation of that metabolite intensity 482 483 across all samples. Subsequently, missing values were imputed using the minimum normalized value for each compound. The normalized and imputed values were used in the association and 484 multivariate linear regression analyses throughout the context. With the exception of the estimation 485 of temporal changes of metabolite intensity in each individual, the original intensities of specified 486 487 metabolites in W0 were subtracted from their original intensity in W4 (or W8, W14).

Statistical analyses. Prior to downstream analysis, metagenomic and metabolomic were combined.
 Samples with complete profiles of both types were used in the downstream analysis, totalling 64
 samples. Three samples with only metabolomics datasets were excluded. From a total of 108

nutrients, 59 nutrient features were selected based on domain knowledge. These features, measured 491 in various units, were log-transformed before we adjusted them for total energy intake to get the 492 nutrient densities. This was followed by Lasso regression utilizing the `glmnet` library in RStudio 493 to select significant dietary features (predictors) that are non-zero [60]. The response variable was 494 495 the corresponding ALP value. Subsequently, we incorporated the selected features and included patient ages as an additional variable to construct a linear model. The coefficients and p-values 496 were extracted for statistical significance. For each patient, the Change of ALP value is estimated 497 by subtracting the baseline ALP (W0) from the ALP at W4 (or W8, W14), then dividing by the 498 499 baseline ALP (W0). Then for each disease category (PSC-UC/PSC-CD/PSC-alone), the Potential to Response was further calculated as the number of samples with reduced ALP value divided by 500 the total number of samples. Alpha diversity of gut microbiota was estimated using the Shannon 501 index and microbial richness (detected species counts). Principal coordinates analysis was 502 performed using the bray-curtis distance of the relative abundance of species in all samples. 503 504 Metabolite set enrichment analysis (MSEA) was conducted quantitatively through the online platform of MetaboAnalyst 5.0 [36]. 505

506 Linear regression models. We used multivariate linear regression models to identify potential 507 microbial markers distinguishing responders from non-responders after LPD. Abundances were 508 fitted with the following species-specific linear mixed-effects model,

510

(Formula 1)

In each species-specific multivariate model, the abundance of each species was modeled as the function of the binary response outcomes (responders/non-responders, with non-responder as reference) within each individual (as random effect), while adjusting for diagnostic categories (PSC-UC/PSC-CD/PSC-alone, with PSC-alone as reference), genders (male/female, with male as reference), age (continuous variable) and BMI (continuous variable). MaAsLin2 [61] in RStudio was the package used to fit the model, with p-values adjusted for multiple hypothesis testing and a target FDR of 0.2.

Separately, another series of multivariate linear regression models were fitted to find a differential
abundance of features after LPD versus baseline using microbial profile, metabolic profile, and
microbial functional profile, respectively. The model is as below,

521

feature ~ treatment stages + diagnostic categories + gender + age +BMI + $(1 | individual) + \epsilon$

522

(Formula 2)

The difference between this model and the previous one is that the abundance of each feature is modeled as the function of the treatment stage (baseline/after LPD, with baseline as reference) instead of response results, while the rest fixed effect and random effect are not changed. The baseline corresponds to samples in W0, while after LPD corresponds to samples in W4 and W8.

- 527 Only those with a response of ALP were considered to fit these models to explain the dietary effects528 of the LPD.
- 529 Clinicaltrials.gov ID: NCT04678219

Author Contributions. JK,YYL, GS, DB, MA, LG, FS, ES, and CB designed the project. GS led
the clinical trial. XY led the data analysis and manuscript preparation. JK, YYL, GS, ZS, SK, DB,
SDM, MA, SH, TC, MP, NJ, MD, AA, LG, FS, ES, and CB interpreted the results. XY prepared
the manuscript. GS, JK, and YYL edited the manuscript. All authors reviewed and approved the
manuscript. JK and YYL supervised the study.

- **Declaration of Interests.** No potential competing interest was reported by the authors.
- 539 Acknowledgements. This work was supported by the Resnek Family Center for PSC Research.

542 **REFERENCES**

- Hov, J.R. and T.H. Karlsen, *The microbiota and the gut-liver axis in primary sclerosing cholangitis*. Nat Rev Gastroenterol Hepatol, 2022.
- Sayed, A., et al., *Predictors and Outcomes of Biologic/Immunosuppressive Therapy for PSC-Associated IBD.* Gastroenterology, 2022. 162(3): p. S76.
- 5473.Mertz, A., et al., Primary sclerosing cholangitis and inflammatory bowel disease548comorbidity: an update of the evidence. Ann Gastroenterol, 2019. 32(2): p. 124-133.
- 4. Hsu, C.L. and B. Schnabl, *The gut-liver axis and gut microbiota in health and liver disease*.
 Nat Rev Microbiol, 2023. 21(11): p. 719-733.
- 5. Jiang, X. and T.H. Karlsen, *Genetics of primary sclerosing cholangitis and pathophysiological implications*. Nature Reviews Gastroenterology & Hepatology, 2017.
 14(5): p. 279-295.
- Hov, J.R. and T.H. Karlsen, *The microbiota and the gut–liver axis in primary sclerosing cholangitis*. Nature Reviews Gastroenterology & Hepatology, 2023. 20(3): p. 135-154.
- Timur, L., et al., *Alterations of the bile microbiome in primary sclerosing cholangitis*. Gut, 2020. 69(4): p. 665.
- Vieira-Silva, S., et al., *Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses.* Nat
 Microbiol, 2019. 4(11): p. 1826-1831.
- 561 9. Fitzpatrick, J.A., et al., *Dietary management of adults with IBD the emerging role of dietary therapy*. Nat Rev Gastroenterol Hepatol, 2022. 19(10): p. 652-669.
- Lloyd-Price, J., et al., *Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.* Nature, 2019. 569(7758): p. 655-662.
- Federici, S., et al., *Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation*. Cell, 2022.
 185(16): p. 2879-2898 e24.
- 568 12. Zhang, Y., et al., *Discovery of bioactive microbial gene products in inflammatory bowel*569 *disease*. Nature, 2022. 606(7915): p. 754-760.
- Hov, J.R. and M.J.C.O.i.G. Kummen, *Intestinal microbiota in primary sclerosing cholangitis*. 2016. 33: p. 85–92.
- Kentaro, I., et al., *Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis*. Gut, 2017. 66(7): p. 1344.
- 15. Nakamoto, N., et al., *Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis*. Nature Microbiology,
 2019. 4(3): p. 492-503.
- Kummen, M., et al., *Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis*. Gastroenterology, 2021. 160(5): p. 1784-1798 e0.
- 579 17. Liu, Q., et al., Altered faecal microbiome and metabolome in IgG4-related sclerosing
 580 cholangitis and primary sclerosing cholangitis. Gut, 2022. 71(5): p. 899-909.

- 18. Ichikawa, M., et al., *Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis*. Nat Commun, 2023. 14(1): p.
 3261.
- Wolfson, S.J., et al., *Bacterial hydrogen sulfide drives cryptic redox chemistry in gut microbial communities.* Nature Metabolism, 2022. 4(10): p. 1260-1270.
- Barton, L.L., et al., *Sulfur Cycling and the Intestinal Microbiome*. Digestive Diseases and
 Sciences, 2017. 62(9): p. 2241-2257.
- Pitcher, M.C.L., E.R. Beatty, and J.H. Cummings, *The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.*Gut, 2000. 46(1): p. 64.
- 591 22. Próchnicki, T., et al., *Mitochondrial damage activates the NLRP10 inflammasome*. Nature
 592 Immunology, 2023. 24(4): p. 595-603.
- Lewis, J.D., et al., A Randomized Trial Comparing the Specific Carbohydrate Diet to a
 Mediterranean Diet in Adults With Crohn's Disease. Gastroenterology, 2021. 161(3): p.
 837-852.e9.
- Cohen, S.A., et al., *Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease*. J Pediatr Gastroenterol Nutr, 2014. 59(4): p. 516-21.
- 598 25. Wastyk, H.C., et al., *Gut-microbiota-targeted diets modulate human immune status*. Cell,
 599 2021. 184(16): p. 4137-4153.e14.
- Slomski, A., *Mediterranean Diet vs Low-fat Diet for Patients With Heart Disease*. Jama,
 2022. 327(24): p. 2386.
- Longo, V.D. and R.M. Anderson, *Nutrition, longevity and disease: From molecular mechanisms to interventions.* Cell, 2022. 185(9): p. 1455-1470.
- Kahleova, H., S. Levin, and N.D. Barnard, *Vegetarian Dietary Patterns and Cardiovascular Disease*. Prog Cardiovasc Dis, 2018. 61(1): p. 54-61.
- 606 29. Gentile, C.L. and T.L. Weir, *The gut microbiota at the intersection of diet and human health.*607 Science, 2018. 362(6416): p. 776-780.
- 60830.Corbin, K.D., et al., Host-diet-gut microbiome interactions influence human energy609balance: a randomized clinical trial. Nat Commun, 2023. 14(1): p. 3161.
- Bajaj, J.S., S.C. Ng, and B. Schnabl, *Promises of microbiome-based therapies*. Journal of
 Hepatology, 2022. 76(6): p. 1379-1391.
- 612 32. Liwinski, T., et al., A prospective pilot study of a gluten-free diet for primary sclerosing
 613 cholangitis and associated colitis. Aliment Pharmacol Ther, 2023. 57(2): p. 224-236.
- 614 33. Wishart, D.S., et al., *HMDB 5.0: the Human Metabolome Database for 2022*. Nucleic
 615 Acids Res, 2022. 50(D1): p. D622-d631.
- Kanehisa, M., et al., *KEGG for taxonomy-based analysis of pathways and genomes.*Nucleic Acids Res, 2023. 51(D1): p. D587-d592.
- 618 35. Kim, S., et al., *PubChem 2023 update*. Nucleic Acids Research, 2022. 51(D1): p. D1373619 D1380.

- Bang, Z., et al., Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nature Protocols, 2022.
 17(8): p. 1735-1761.
- 37. Xia, J. and D.S. Wishart, *MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data*. Nucleic Acids Research, 2010. 38(suppl_2): p. W71-W77.
- 38. Weininger, D., et al., *SMILES. 2. Algorithm for generation of unique SMILES notation.*1989. 29(2): p. 97-101.
- Wolf, P.G., et al., *Diversity and distribution of sulfur metabolic genes in the human gut microbiome and their association with colorectal cancer*. Microbiome, 2022. 10(1): p. 64.
- 40. Marcelino, V.R., et al., *Disease-specific loss of microbial cross-feeding interactions in the human gut*. Nat Commun, 2023. 14(1): p. 6546.
- Heinken, A., et al., Systematic assessment of secondary bile acid metabolism in gut *microbes reveals distinct metabolic capabilities in inflammatory bowel disease.*Microbiome, 2019. 7(1): p. 75.
- 42. Lobel, L., et al., *Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function*. 2020. 369(6510): p. 1518-1524.
- Blachier, F., M. Beaumont, and E. Kim, *Cysteine-derived hydrogen sulfide and gut health: a matter of endogenous or bacterial origin.* Curr Opin Clin Nutr Metab Care, 2019. 22(1):
 p. 68-75.
- 640 44. Guzior, D.V. and R.A. Quinn, *Review: microbial transformations of human bile acids*.
 641 Microbiome, 2021. 9(1): p. 140.
- 642 45. Collins, S.L., et al., *Bile acids and the gut microbiota: metabolic interactions and impacts*643 *on disease.* Nature Reviews Microbiology, 2023. 21(4): p. 236-247.
- 46. Xing, K., et al., Roseburia intestinalis generated butyrate boosts
 anti-PD-1 efficacy in colorectal cancer by activating cytotoxic
 CD8<sup>+</sup> T cells. Gut, 2023. 72(11): p. 2112.
- 47. Nie, K., et al., *Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in*648 *Genus and Species.* 2021. 11.
- 48. Stummer, N., et al. *Role of Hydrogen Sulfide in Inflammatory Bowel Disease*. Antioxidants, 2023. 12, DOI: 10.3390/antiox12081570.
- 49. Teigen, L.M., et al. *Dietary Factors in Sulfur Metabolism and Pathogenesis of Ulcerative Colitis*. Nutrients, 2019. 11, DOI: 10.3390/nu11040931.
- 653 50. Rowan, F.E., et al., Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of
 654 ulcerative colitis. British Journal of Surgery, 2009. 96(2): p. 151-158.
- 51. Khalil, N.A., et al., *In vitro batch cultures of gut microbiota from healthy and ulcerative colitis (UC) subjects suggest that sulphate-reducing bacteria levels are raised in UC and by a protein-rich diet.* International Journal of Food Sciences and Nutrition, 2014. 65(1):
 p. 79-88.

- 52. Jowett, S.L., et al., *Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study*. Gut, 2004. 53(10): p. 1479.
- 53. Magee, E.A., et al., *Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans123*. The American Journal
 of Clinical Nutrition, 2000. 72(6): p. 1488-1494.
- 54. Day, A.S., et al., *Therapeutic Potential of the 4 Strategies to SUlfide-REduction (4-SURE) Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open-Label Feasibility Study.* The Journal of Nutrition, 2022. 152(7): p. 1690-1701.
- 55. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015
 668 2020 Dietary Guidelines for Americans. 8th Edition. December 2015.
- 56. Tuttle, S.G., et al., *Further Observations on the Amino Acid Requirements of Older Men: II. Methionine and Lysine.* The American Journal of Clinical Nutrition, 1965. 16(2): p. 229231.
- 672 57. Gottschall, E., *Breaking the vicious cycle: intestinal health through diet*. 1994: Kirkton,
 673 Ont.: Kirkton Press.
- 58. Blanco-Míguez, A., et al., *Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4*. Nature Biotechnology, 2023. 41(11): p. 16331644.
- 59. Beghini, F., et al., *Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3.* eLife, 2021. 10: p. e65088.
- 679 60. Friedman, J.H., T. Hastie, and R. Tibshirani, *Regularization Paths for Generalized Linear*680 *Models via Coordinate Descent*. Journal of Statistical Software, 2010. 33(1): p. 1 22.
- 681 61. Mallick, H., et al., *Multivariable association discovery in population-scale meta-omics*682 *studies.* PLOS Computational Biology, 2021. 17(11): p. e1009442.
- 683

Table 1 Patients' characteristics at inclusion.		
	LPD (n=10)	SCD (n=10)
Age at inclusion (years) ^a	43.79 ± 10.05	43.95 ± 8.99
Gender (male/female)	10 (7/3)	10 (4/6)
Diagnosis ^b		
PSC-UC	6 (60%)	4 (40%)
PSC-CD	1 (10%)	2 (20%)
PSC-alone	3 (30%)	4 (40%)
BMI ^a	26.89 ± 6.69	23.53 ± 3.77
Smoker=yes ^b	3 (30%)	2 (20%)

 $685 \qquad ^{a} Mean \pm SD$

686 ^b n (%)

687 UC, ulcerative colitis; CD, Crohn's disease; IBD, inflammatory bowel disease; PSC, primary

688 sclerosing cholangitis; BMI, Boby mass index.



Figure 1. Overview of the study design. Two dietary interventions: Low protein/low sulfur diet (LPD) and Specific carbohydrate diet (SCD) were compared. We profiled fecal metagenomic and metabolomic data at four time points. 3-day dietary records, co-diagnosis of IBD (UC, CD, or non-IBD), and clinical parameters were collected. After dietary interventions, the response outcomes and temporal trajectory were analyzed and interpreted through multiple perspectives.



Figure 2. LPD dietary intervention benefits patients with PSC, whereas SCD exacerbates the 699 condition. a) Protein intake in LPD and SCD. Each line represents an individual. Protein intake 700 701 amount was adjusted by the total energy intake to estimate the nutrient density. b) Percent change in alkaline phosphatase (ALP) from baseline before, during and after dietary intervention. Each 702 line represents an individual. c) Coefficients of selected nutrient features after Lasso regression, 703 indicating that reduced methionine intake significantly lowers ALP values. Nutrients with 704 significance in the regression model were plotted, with *** denoting strong significance (p-value 705 < 0.001), ** very significant (0.001< p-value < 0.01), * significant (0.01< p-value < 0.05). d-f) 706 707 Variations in ALP values and the potential rates to respond indicated differing responses among three disease categories, d) PSC-UC, e) PSC-CD, and f) PSC-alone. The Wilcoxon rank-sum test 708 was employed to assess significance between LPD and SCD, with *** denoting strong significance 709 710 (p-value < 0.001), and 'ns' indicating no significant difference (p-value > 0.05).



Figure 3. Fecal metagenomics predicts response outcomes. a) PCoA plot of the gut microbial compositions of LPD samples, differentiated by response outcomes (blue for responders: individuals showing decreased ALP, and pink for non-responders: individuals showing increased ALP, shows that LPD responders have distinct microbial structure from LPD non-responders. Arrows were drawn to connect samples from the same individuals in chronological order. b) Heatmap of bacterial species markers that can distinguish LPD responders from non-responders and the abundance distribution of these markers correlate with disease categories, as determined

- by multivariate linear regression models (target p-value < 0.05 and FDR < 0.2). Each column in
- the heatmap is a sample, and all the samples including both LPD responders and LPD non-
- responders are clustered based on the similarity of the bacterial composition. Each row is a species,
- and species are clustered based on the similarity of the distribution pattern across samples of the
- specified species. c) PCA plot of the gut metabolite compositions of LPD samples, differentiated
- by response outcomes (blue and pink), with arrows to connect samples from the same individuals
- in chronological order. d) Heatmap of metabolite markers that can distinguish LPD responders
- from non-responders. The columns in this heatmap are arranged to correspond directly with the
- order of the columns in the microbial profile heatmap in Fig. 3b.



Figure 4. The fecal metabolomics predicts the disease improvement trajectory under LPD in 729 those LPD responders. a) Volcano plot derived from multivariate linear regression models, using 730 time series metabolite intensity profiles from W0, W4, and W8 and adjusting for covariates 731 including disease categories. The metabolites were colored according to the class subclasses. **b**) 732 733 Metabolite set enrichment analysis (MSEA) of selected metabolites with significant diet-induced changes after the regression model in Fig.3a (MetaboAnalyst v5.0, p-value < 0.05). c-f) Temporal 734 changes in four key sulfur metabolism metabolites, including methionine, methionine sulfone, 735 taurine, and cysteine. Bars are colored blue to represent metabolites that decreased after LPD, and 736 orange for those that increased. The Wilcoxon signed-rank test was employed to assess 737 significance between sampling time points, with * denoting significance (0.01 < p-value < 0.05), 738 and 'ns' indicating no significant difference (p-value > 0.05). g-j) The relationship between each 739 of the four metabolites and ALP values tested using Spearman correlation. Cysteine shows a 740 negative association with ALP values, whereas the other three metabolites have no significant 741 association (p-value < 0.05). k) Characterized and proposed sulfur-related metabolic pathways in 742 response to LPD intervention benefiting patients with PSC. Metabolites and genes that increased 743 are colored red, those that decreased are blue, while those without significant changes are gray 744 (Wilcoxon signed-rank test, p-value < 0.05). Abbreviations used are as follows: MSF: methionine-745 sulfone; Hyc: homocysteine; Ctt: cystathionine; LA: L-alanine; 3-MP: 3-Mercaptopyruvate; 746 Tauro-CA: taurocholic acid; CA: cholic acid. 747









Figure 5. Microbial sulfur metabolism and associated bacterial species. a) Interactions among 750 microbial sulfur metabolism genes, related metabolites, and relevant microbial species. Nodes 751 were colored blue to represent features that decreased after LPD and red for those features that 752 increased. Edge gradients represent the coefficients of Spearman correlation between the 753 754 abundance (or intensity) of nodes. Only associations deemed significant, with FDR < 0.05, are shown here. **b-c**) Shifts in the stratified abundance of bacterial species for two represent genes (bsh 755 and *cvsK*) after dietary treatments. Each column is a sample, with the left panel on a purple 756 background representing LPD responders under intervention, and the right panel on a pink 757 background corresponding to samples from the SCD treatments. We subtracted the stratified 758 abundance in each sample from its corresponding baseline to calculate the gene's change amount. 759 Each column contains stacked bars, with each bar representing the change in stratified abundance 760 of a specific bacterial species identified as hosts of the specified genes. Values below the y=0 line 761 indicate a decrease, while those above indicate an increase. Species are colored only if their 762 stratified abundances showed significant changes (either increases or decreases) at W4 (or W8) 763 compared to the baseline in LPD responders. The unit 'cpm' represents counts per million. **d-e**) 764 Temporal changes of two key bacteria involved in sulfur metabolism: d) *Eggerthella lenta* and e) 765 Roseburia intestinalis. Bars are colored blue to represent metabolites that decreased after LPD, 766 and orange for those that increased. The Wilcoxon rank-sum test was employed to assess 767 significance between sampling time points, with ** denoting very significant changes (0.001< p-768 value < 0.01), * significant (0.01 < p-value < 0.05), and 'ns' indicating no significant difference (p-769 value > 0.05). 770